已收盤 10-12 16:00:00 美东时间
0.000
0.00%
证券之星消息,截至2026年11月4日收盘,汇量科技(01860.HK)报收于9.52港元,上涨4.04%,成交量635.87万股,成交额5976.42万港元。
11-04 22:01
11月4日,Mint Inc Ltd(MIMI)收平,报0.96美元,成交额89.78万美元,市值1424.97万美元。 行情数据 • 开盘价:0.9美元 •...
11-04 08:51
Gold.com appoints Nick Bowkett as Vice President of Trading and Business Development to accelerate growth in Europe. With over 16 years at The Royal Mint, Bowkett brings extensive experience in precious metals and global expansion. Gold.com, a leading alternative assets platform, aims to unify its wholesale and direct-to-consumer capabilities across Europe.
11-02 13:00
Nuclea Energy and NorthStrive Acquisition Corp I have entered into a definitive business combination agreement, valuing Nuclea at $350 million. The transaction is expected to close in the first half of 2027, making Nuclea a publicly traded company under the name Nuclea-X Inc. Nuclea is developing advanced nuclear technologies, including the Morpheus Micro Modular Reactor, to meet growing demand for reliable, carbon-free electricity, particularly ...
11-02 12:00
Beta Bionics公布2026财年第三季度营收同比增长30%至3550万美元,收窄了全年营收指引,并详细说明了与Mint相关的营收递延情况及产品计划。
10-28 09:11
Beta Bionics 2026年第三季度财报电话会:销售额增长30%至3550万美元,上调2026年业绩指引,Mint的推出计划仍定于2027年第一季度。
10-28 08:04
Beta Bionics Q3 2026 earnings call: sales rose 30% to $35.5 million, 2026 guidance increased, and the Mint launch remains set for Q1 2027.
10-28 08:00
Gold.com, Inc. (NYSE: GOLD) will hold a conference call on November 4, 2026, at 4:30 p.m. Eastern time to discuss its fiscal first quarter 2026 results. The call will include a presentation by management followed by a Q&A session. The webcast and dial-in details are provided, with a replay available later the same day. Gold.com, founded in 1965, offers precious metals and collectibles through its integrated platform and operates globally.
10-23 12:30
Melbourne, Australia and Indianapolis, October 21, 2026 – Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has provided a financial update for Q3 2026, highlighting strong revenue growth of 19% to US$245 million, driven by demand for its PSMA products. Precision Medicine revenue rose 30% to US$201 million, with FDA approval of Pixclara for glioma imaging and completion of enrollment for the BiPASS Phase 3 study. The company also announced a ...
10-20 22:10